Brit J Cancer:激素原发性多病灶前列腺癌和匹配的淋巴结转移转录组探索

2018-12-05 AlexYang MedSci原创

目前对原发性前列腺癌(PC)预测能力的不足将会导致该疾病发生转移,同样导致良性PCs的过度治疗和恶性PCs的治疗不足。最近,有研究人员探索了多病灶激素原发性PC转移过程发生过程中的转录变化情况。研究人员使用了RNA测序的方法分析了23个激光显微切割原发性PC病灶位点和23个临近的正常前列腺组织样本,以及9个淋巴结转移位点。这些样本来自于10名激素原发性PC患者,并利用差异基因表达分析和聚类分析鉴定

目前对原发性前列腺癌(PC)预测能力的不足将会导致该疾病发生转移,同样导致良性PCs的过度治疗和恶性PCs的治疗不足。最近,有研究人员探索了多病灶激素原发性PC转移过程发生过程中的转录变化情况。

研究人员使用了RNA测序的方法分析了23个激光显微切割原发性PC病灶位点和23个临近的正常前列腺组织样本,以及9个淋巴结转移位点。这些样本来自于10名激素原发性PC患者,并利用差异基因表达分析和聚类分析鉴定了PC发展过程中的重要基因。研究人员还开发了2个基于多重基因的表达特性模型,并利用Cox回归和Kaplan-Meier分析在3个独立的根治性前列腺切除术(RP)群体中(>650人)评估了他们的预后价值。研究人员鉴定了一些新的与PC相关的转录本在PC发展过程中下调,并且这些转录本用来开发2个新的基于基因表达的预后模型。模型表明了在3个RP群体中具有独立的预后能力(n=405, n=107和n=91),并利用RP后生化复发作为主要临床结点。

最后,研究人员指出,他们鉴定了一些在PC发展过程中下调的基因,并开发了2个新的PC风险分层预后模型,这2种模型均具有独立的预测能力,且不受常规临床病理因素的影响。

原始出处:

Linnéa Schmidt, Mia MØller, Christa Haldrup et al. Exploring the transcriptome of hormone-naive multifocal prostate cancer and matched lymph node metastases. Brit J Cancer. 19 Nov 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1846733, encodeId=ee461846e33ba, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Fri Jul 05 22:55:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747337, encodeId=80191e4733703, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Fri Mar 29 16:55:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293052, encodeId=012912930521f, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Dec 07 03:55:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302516, encodeId=f561130251616, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Dec 07 03:55:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420186, encodeId=4eb8142018635, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Fri Dec 07 03:55:00 CST 2018, time=2018-12-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1846733, encodeId=ee461846e33ba, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Fri Jul 05 22:55:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747337, encodeId=80191e4733703, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Fri Mar 29 16:55:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293052, encodeId=012912930521f, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Dec 07 03:55:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302516, encodeId=f561130251616, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Dec 07 03:55:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420186, encodeId=4eb8142018635, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Fri Dec 07 03:55:00 CST 2018, time=2018-12-07, status=1, ipAttribution=)]
    2019-03-29 mjldent
  3. [GetPortalCommentsPageByObjectIdResponse(id=1846733, encodeId=ee461846e33ba, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Fri Jul 05 22:55:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747337, encodeId=80191e4733703, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Fri Mar 29 16:55:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293052, encodeId=012912930521f, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Dec 07 03:55:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302516, encodeId=f561130251616, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Dec 07 03:55:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420186, encodeId=4eb8142018635, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Fri Dec 07 03:55:00 CST 2018, time=2018-12-07, status=1, ipAttribution=)]
    2018-12-07 sodoo
  4. [GetPortalCommentsPageByObjectIdResponse(id=1846733, encodeId=ee461846e33ba, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Fri Jul 05 22:55:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747337, encodeId=80191e4733703, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Fri Mar 29 16:55:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293052, encodeId=012912930521f, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Dec 07 03:55:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302516, encodeId=f561130251616, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Dec 07 03:55:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420186, encodeId=4eb8142018635, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Fri Dec 07 03:55:00 CST 2018, time=2018-12-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1846733, encodeId=ee461846e33ba, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Fri Jul 05 22:55:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747337, encodeId=80191e4733703, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Fri Mar 29 16:55:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293052, encodeId=012912930521f, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Dec 07 03:55:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302516, encodeId=f561130251616, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Dec 07 03:55:00 CST 2018, time=2018-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420186, encodeId=4eb8142018635, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Fri Dec 07 03:55:00 CST 2018, time=2018-12-07, status=1, ipAttribution=)]

相关资讯

ARCH PATHOL LAB MED:前列腺癌抗原3和前列腺特异性抗原的组合可提高患有前列腺癌风险男性的诊断准确性

前列腺癌抗原3(PCA3)是一种非编码RNA,在前列腺癌(PCa)组织中高度过表达,在PCa患者尿液中有排泄。本研究的目的是评估尿PCA3在PCa风险男性中的临床应用价值。 研究人员回顾性地调查了一组271名男性(中位年龄为63岁),其中前列腺特异性抗原(PSA)升高,和/或家族史明显,和/或直肠指检异常。对诊断敏感性,特异性,阳性和阴性预测值(PPV,NPV),阳性和阴性似然比(LR +,

Pharmacotherapy:前列腺癌患者雄激素剥夺治疗相关的主要长期副作用有哪些?

2018年10月,美国学者发表在《Pharmacotherapy》的一项研究,考察了前列腺癌男性雄激素剥夺治疗(ADT)相关的主要长期副作用风险。

Prostate Cancer P D:低风险前列腺癌中,直接治疗和积极监测比较

最近,有研究人员对非常低风险前列腺癌患者的治疗选择进行了研究,并且评估了与医院相关因素的作用。研究包括了2015年和2016年之间鉴定为非常低风险前列腺癌的所有患者((cT1c-cT2a, PSA<10ng/ml, 格林森得分<7,以及<3阳性病灶)。研究人员利用多层次逻辑回归分析调查了直接治疗与积极监测(AS),并评估了患者、肿瘤和医院相关因素的影响。总的来说,2396名患者中

Communications Biology:IFNL4-ΔG 与男性前列腺癌相关

性传播感染能够到达前列腺,并且上述感染的有害作用可以通过先天免疫进行调控,包括了干扰素的作用。在编码干扰素λ4的IFNL4基因中,人类在rs368234815-TT/ΔG中的生殖系二核苷酸变异具有多态性。由于IFNL4-ΔG等位基因与受损的病毒清除能力有关,研究人员假设通过终生性伴侣数量的评估性传播病原体的潜在接触,并指出性传播病原体的潜在接触也许能够增加前列腺癌的风险,并且是IFNL4-ΔG依赖

Radiology: 68Ga-PSMA-11 PET/MRI与多参数MRI诊断前列腺癌哪个更好?

本研究旨在比较68Ga-前列腺特异性膜抗体(PSMA-11)PET/MRI与多参数MRI诊断前列腺癌的准确性。

中国前列腺癌患者五年生存率只有美国一半,专家呼吁加强筛查

“近年来统计数据显示,我国前列腺癌患者5年生存率仅为53.5%,而美国前列腺癌患者的5年生存率达到了99%。”12月4日上午,在第八届上海泌尿肿瘤国际论坛召开前夕,中国抗癌协会泌尿男生殖系肿瘤专业委员会候任主委、复旦大学附属肿瘤医院副院长叶定伟教授在接受澎湃新闻(www.thepaper.cn)记者采访时透露了这一消息。叶定伟表示,中国目前没有明确前列腺癌的筛查标准,老百姓筛查意识不够强烈,这导致